View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
June 22, 2021updated 12 Jul 2022 11:06am

EHA 2021: primary endpoints met in final analysis of EURO-SKI trial in CML

Results from the EURO-SKI trial suggest tyrosine kinase inhibitor treatment duration and deep molecular response duration could be important prognostic markers in chronic myeloid leukaemia (CML).

By GlobalData Healthcare

At this year’s virtual European Haematology Association (EHA) meeting, held on 9–17 June, the final results from the EURO-SKI study were presented. EURO-SKI investigated the duration of treatment-free molecular response following tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic myeloid leukaemia (CML). The study found that at the three-year follow-up, 46% of patients continued to experience molecular recurrence-free survival without restarting treatment. A major molecular response (MMR) was defined as BCR-ABL1 levels of less than 0.01%. Further evaluation is now ongoing to identify prognostic markers that indicate patients who will be good candidates for treatment discontinuation.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A total of 868 patients were enrolled between May 2012 and December 2014. To be enrolled, patients had to have received at least three years of TKI therapy and demonstrate a deep molecular response (BCR-ABL1 transcript levels of <0.01%) for at least one year. Following a screening phase, patients then discontinued TKI treatment and underwent four to six-week monitoring within the first year. During the second and subsequent years, monitoring was reduced to three-month intervals. Follow-up occurred at six months and three years, with data on 728 patients available at the three-year mark.

Previously reported interim results found that 62% of patients continued to have a treatment-free MMR at six months. Upon final analysis, 61% of patients were found to be in MMR at six months, meeting the first primary endpoint of the trial, prompting the null hypothesis of less than 40% MRR at six months to be rejected. The second primary endpoint was also met, as 46% of patients were in MMR at three years, leading to the rejection of the null hypothesis of 35% of patients or less being in MMR.

Since the introduction of TKIs, the life expectancy of CML patients has approached that of the general population. Treatment-free remission is now frequently discussed, with treatment guidelines including recommendations on the management of treatment cessation for patients with deep molecular responses who have been on TKIs for several years. There are, however, variations between treatment guidelines. For example, the National Comprehensive Cancer Network recommends patients to have been on TKIs for at least three years before considering discontinuation, whereas the European Society for Medical Oncology recommends patients to have been on TKIs for at least five years. In both cases, certain other factors must also be considered.

While it is clear that many CML patients can experience prolonged treatment-free remission, there is a lack of prognostic markers that can aid in treatment decisions. The interim results from the EURO-SKI trial gave evidence that TKI treatment duration and the duration of deep molecular response could both be important prognostic markers. Further analysis of the final results will be important to help define future treatment guidelines and potentially allow more patients to discontinue treatment, thus reducing costs to healthcare systems and saving patients from unwanted treatment-related side-effects.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena